A number of important neurologic, mental health and drug abuse problems involve dysfunctioning or losses of the monoarninergic systems of the human brain, and in particular the dopaminergic neurons. In vivo imaging of these systems using radiopharmaceuticals and Positron Emission Tomography (PET provides a unique and valuable approach to the study of these diseases in the living human brain. Choices of appropriate radiotracers, alone and in combinations, will be crucial for the success of such in vivo imaging. This Project will examine animal models of such diseases, using a novel approach of dual in vivo radiotracer studies of the vesicular monoamine transporter (VMAT2 and the dopamine neuronal membrane transporter (DAT). The potential in vivo regulation of these binding sites by disease processes and chronic drug treatments will be evaluated. The short term regulation of such transporters b kinase-mediated phosphorylation reactions will be studied. The relationship between the two transporters, proposed here as markers of nerve terminal integrity (VMAT2) and nerve terminal function (DAT), will be examined over tim in models of degeneration and recovery in animal models of Parkinson's disease and drug abuse. Studies will subsequently be done to determine whether measure of numbers of terminals (VMAT2), functional status (DAT), or function on a per terminal basis (DAT/VMAT'2) provides the best sensitivity for measuring in viv the effects of current and new therapeutic approaches to changing the course o these diseases. This Project will provide crucial information on the proper approach to be taken for in vivo tomographic radionuclide of monoaminergic terminal-related disease inception, progression or treatment in a general patient population. Finally, synthetic radiochemistry efforts will be undertaken to extend this approach to measuring the VMAT2 outside the heavily-dopaminergic innervated striaturn, opening up new avenues of research into the role of monoaminergic (particularly, serotonergic and adrenergic) terminals in a wider variety of neurologic, mental health and drug abuse diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH047611-09
Application #
6186417
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Meinecke, Douglas L
Project Start
1991-09-01
Project End
2001-08-31
Budget Start
2000-07-01
Budget End
2001-08-31
Support Year
9
Fiscal Year
2000
Total Cost
$258,619
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Pichika, Rama; Jewett, Douglas M; Sherman, Philip S et al. (2010) Synthesis and in vivo brain distribution of carbon-11-labeled ?-opioid receptor agonists. Nucl Med Biol 37:989-96
Nickell, Justin R; Krishnamurthy, Sairam; Norrholm, Seth et al. (2010) Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J Pharmacol Exp Ther 332:612-21
Zheng, Guangrong; Dwoskin, Linda P; Deaciuc, Agripina G et al. (2005) Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg Med Chem 13:3899-909
Zheng, Guangrong; Dwoskin, Linda P; Deaciuc, Agripina G et al. (2005) Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem 48:5551-60
Zheng, Guangrong; Dwoskin, Linda P; Deaciuc, Agripina G et al. (2005) Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands. Bioorg Med Chem Lett 15:4463-6
Kilbourn, Michael R; Kemmerer, Elyse S; Desmond, Timothy J et al. (2004) Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain. Exp Neurol 188:387-90
Kilbourn, Michael R (2004) Long-term reproducibility of in vivo measures of specific binding of radioligands in rat brain. Nucl Med Biol 31:591-5
Jewett, Douglas M; Kilbourn, Michael R (2004) In vivo evaluation of new carfentanil-based radioligands for the mu opiate receptor. Nucl Med Biol 31:321-5
Kemmerer, Elyse S; Desmond, Timothy J; Albin, Roger L et al. (2003) Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol 183:81-6
Kilbourn, Michael R; Sherman, Phillip S; Kuszpit, Kyle (2002) In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies. Synapse 43:188-94

Showing the most recent 10 out of 44 publications